致密乳腺补充自动全乳超声BI-RADS 3病变恢复常规筛查的前瞻性结局
前瞻性纳入2257例致密乳腺女性行补充自动全乳超声,BI-RADS 3占17.5%;394例2年随访中病变象限无癌(0%,95%CI 0.0-0.9%),BI-RADS 1、2、3恶性率无差异(p=.28),ABUS召回率3.8%,若对BI-RADS 3行短期随访召回率将达21.3%。结论支持ABUS BI-RADS 3恢复常规年度随访。
要点
- 补充ABUS BI-RADS 3病变2年随访病变象限癌检出率为0%,支持恢复常规筛查。
- ABUS BI-RADS 3恢复常规筛查使召回率从21.3%降至3.8%,减少短期随访。
- ABUS BI-RADS 1、2、3恶性率无差异(p=.28),BI-RADS 3并非高风险。
核心结论
- 对补充ABUS发现的BI-RADS 3病变建议恢复常规筛查,可大幅降低召回率且 unlikely 导致不良结局。
研究设计与样本
- 前瞻性研究,纳入2257例乳腺X线筛查BI-RADS 1或2且乳腺密度C或D的女性,行补充自动全乳超声(ABUS)。
- ABUS评为BI-RADS 1、2、3者建议恢复常规筛查,BI-RADS 0者行靶向手持超声,其余随访2年。
- 恶性率比较采用Fisher精确检验,试验注册号NCT02650778。
诊断标准与关键数值
- ABUS BI-RADS 3共395例(17.5%),394例完成2年随访,病变象限癌检出率0%(95%CI 0.0-0.9%)。
- 2年随访中乳腺癌诊断:BI-RADS 1为4/1117(0.4%),BI-RADS 2为2/556(0.4%),BI-RADS 3为2/394(0.5%,均位于其他象限)。
- ABUS召回率3.8%(85/2257,95%CI 3.6-4.0%);若对BI-RADS 3行短期随访,召回率将达21.3%(480/2257,95%CI 19.6-23.0%)。
- 活检率0.5%(12/2257,95%CI 0.3-0.9%),活检阳性率58.3%(7/12)。
临床应用与阅片要点
- 补充ABUS评为BI-RADS 3时,可建议恢复常规年度筛查而非短期随访,以降低召回率。
- 报告BI-RADS 3时应注明病变象限,随访中其他象限新发癌不归因于该病变。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
BACKGROUND. Supplemental screening breast ultrasound (US) detects additional cancers in women with dense breasts but identifies many BI-RADS 3 lesions that result in short-term follow-up and biopsies. OBJECTIVE. The purpose of this study was to evaluate outcomes in patients recommended for return to routine screening for lesions assessed as BI-RADS 3 on supplemental automated whole-breast US. METHODS. This prospective study invited patients with BI-RADS 1 or 2 on screening mammography and breast density C or D to undergo supplemental automated breast US (ABUS). ABUS was interpreted as BI-RADS 1, 2, 3, or 0. Return to routine screening was recommended for ABUS BI-RADS 1, 2, or 3. ABUS BI-RADS 0 lesions underwent targeted handheld US. Remaining patients were followed for 2 years. Malignancy rates were compared using Fisher exact tests. RESULTS. A total of 2257 women (mean age, 58.0 ± 11.2 [SD] years) were included. Supplemental ABUS was scored as BI-RADS 1 in 1186 (52.5%) women, BI-RADS 2 in 591 (26.2%), BI-RADS 3 in 395 (17.5%), and BI-RADS 0 in 85 (3.8%). A total of 394 patients with ABUS BI-RADS 3 had 2-year follow-up, during which no cancer (0%; 95% CI, 0.0-0.9%) was diagnosed in the quadrant of the lesion. Among patients with 2-year follow-up, breast cancer was diagnosed in 4/1117 (0.4%) with ABUS BI-RADS 1, 2/556 (0.4%) with ABUS BI-RADS 2, and 2/394 (0.5%) with ABUS BI-RADS 3 (cancer in other quadrant than the lesion). Malignancy rates were not different between ABUS BI-RADS 1, 2, and 3 (p = .28). The ABUS recall rate was 3.8% (85/2257; 95% CI, 3.6-4.0%). If short-term follow-up had been recommended for ABUS BI-RADS 3, the ABUS recall rate would have been 21.3% (480/2257, 95% CI 19.6-23.0%). The biopsy rate was 0.5% (12/2257; 95% CI, 0.3-0.9%); the positive biopsy rate was 58.3% (7/12). One of seven cancers diagnosed by initial supplemental ABUS and none of eight cancers diagnosed during subsequent follow-up were node-positive cancer. CONCLUSION. Return to routine screening for ABUS BI-RADS 3 lesions results in a substantial decrease in recall rate and is unlikely to result in an adverse outcome. CLINICAL IMPACT. This prospective study supports a recommendation for routine annual follow-up for BI-RADS 3 lesions at supplemental ABUS. TRIAL REGISTRATION. ClinicalTrials.gov NCT02650778.
引用
- Barr RG, DeSivestri A, Golatta M, et al. Outcomes of Return to Routine Screening for BI-RADS 3 Lesions Detected at Supplemental Automated Whole-Breast Ultrasound in Women With Dense Breasts: A Prospective Study. AJR Am J Roentgenol. 2021. PMID: 34259039. doi:10.2214/AJR.21.26180
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。